Clinical Trial Update: A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer [Phase 2]

View source ↗

Summary

Prospective Phase II single-arm study evaluating serplulimab with H101 oncolytic virus, short-course radiotherapy, and XELOX as total neoadjuvant therapy for lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• H101 (oncolytic adenovirus H101)
• OXALIPLATIN (Oxaliplatin)
• Serplulimab (serplulimab)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Rectal Neoplasms, Rectal Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING